TY - JOUR
T1 - Investigational dopamine antagonists for the treatment of schizophrenia
AU - Wang, Sheng Min
AU - Han, Changsu
AU - Lee, Soo Jung
AU - Jun, Tae Youn
AU - Patkar, Ashwin A.
AU - Masand, Prakash S.
AU - Pae, Chi Un
N1 - Funding Information:
This work was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare (HI12C0003); however, the funding source had no further role in preparation, data collection, or writing of the paper.
Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/6/3
Y1 - 2017/6/3
N2 - Introduction: Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D2 receptors. Areas covered: We searched for investigational drugs using the key words ‘dopamine’ and ‘schizophrenia’ in American and European clinical trial registers (clinicaltrials.gov; clinicaltrialsregister.eu). Published articles were searched in PubMed, Embase, Medline, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of Science and the Cochrane Central Register of Controlled Trials Library. Expert opinion: The prospect of developing a dopamine antagonist is hopeful. Brexpiprazole and cariprazine, which were agents listed as ‘investigational dopamine antagonists,’ just received FDA approval. Novel agents such as BL 1020, ITI-007, and JNJ-37822681 have solid published data available, and agents such as L-THP, Lu AF35700, S33138, and SB-773812 are under vigorous investigation. However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes.
AB - Introduction: Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D2 receptors. Areas covered: We searched for investigational drugs using the key words ‘dopamine’ and ‘schizophrenia’ in American and European clinical trial registers (clinicaltrials.gov; clinicaltrialsregister.eu). Published articles were searched in PubMed, Embase, Medline, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of Science and the Cochrane Central Register of Controlled Trials Library. Expert opinion: The prospect of developing a dopamine antagonist is hopeful. Brexpiprazole and cariprazine, which were agents listed as ‘investigational dopamine antagonists,’ just received FDA approval. Novel agents such as BL 1020, ITI-007, and JNJ-37822681 have solid published data available, and agents such as L-THP, Lu AF35700, S33138, and SB-773812 are under vigorous investigation. However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes.
KW - Investigational antipsychotics
KW - Phase II
KW - Schizophrenia
KW - agonist
KW - antagonist
KW - dopamine
UR - http://www.scopus.com/inward/record.url?scp=85019961335&partnerID=8YFLogxK
U2 - 10.1080/13543784.2017.1323870
DO - 10.1080/13543784.2017.1323870
M3 - Review article
C2 - 28443355
AN - SCOPUS:85019961335
SN - 1354-3784
VL - 26
SP - 687
EP - 698
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
IS - 6
ER -